InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,306.00
(
0.88%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
81.97
(
0.81%
)
Bitcoin
69,144.51
(
1.79%
)
Post# of 251933
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biotech jim

Send PM Follow Ignore
Followers 49
Posts 644
Boards Moderated 0
Alias Born 05/02/2011

biotech jim

Re: None

Thursday, 08/04/2016 8:15:41 AM

Thursday, August 04, 2016 8:15:41 AM

Post# of 251933
Regeneron Reports Second Quarter 2016 Financial and Operating Results

http://files.shareholder.com/downloads/REGN/2010257391x0x903209/9C150792-3CCA-48AC-8408-C63D8C3478B0/REGN_News_2016_8_4_General_Releases.pdf

August 4, 2016

- Second quarter 2016 EYLEA® (aflibercept) Injection U.S. net sales increased 27% to $831 million versus second quarter 2015

- Second quarter 2016 EYLEA global net sales(1) increased 33% to $1.32 billion versus second quarter 2015

- Biologics License Application for dupilumab in atopic dermatitis submitted in the United States

TARRYTOWN, N.Y., Aug. 4, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2016 and provided a business update...
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up